rs10495562

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_003183.6(ADAM17):​c.2083-60A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.468 in 1,479,208 control chromosomes in the GnomAD database, including 171,241 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.42 ( 14292 hom., cov: 32)
Exomes 𝑓: 0.47 ( 156949 hom. )

Consequence

ADAM17
NM_003183.6 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: -1.98

Publications

18 publications found
Variant links:
Genes affected
ADAM17 (HGNC:195): (ADAM metallopeptidase domain 17) This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biologic processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The encoded preproprotein is proteolytically processed to generate the mature protease. The encoded protease functions in the ectodomain shedding of tumor necrosis factor-alpha, in which soluble tumor necrosis factor-alpha is released from the membrane-bound precursor. This protease also functions in the processing of numerous other substrates, including cell adhesion proteins, cytokine and growth factor receptors and epidermal growth factor (EGF) receptor ligands, and plays a prominent role in the activation of the Notch signaling pathway. Elevated expression of this gene has been observed in specific cell types derived from psoriasis, rheumatoid arthritis, multiple sclerosis and Crohn's disease patients, suggesting that the encoded protein may play a role in autoimmune disease. Additionally, this protease may play a role in viral infection through its cleavage of ACE2, the cellular receptor for SARS-CoV and SARS-CoV-2. [provided by RefSeq, Aug 2020]
IAH1 (HGNC:27696): (isoamyl acetate hydrolyzing esterase 1 (putative)) Enables identical protein binding activity. Predicted to be involved in lipid catabolic process. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BP6
Variant 2-9491211-T-C is Benign according to our data. Variant chr2-9491211-T-C is described in ClinVar as Benign. ClinVar VariationId is 1188897.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.51 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ADAM17NM_003183.6 linkc.2083-60A>G intron_variant Intron 17 of 18 ENST00000310823.8 NP_003174.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ADAM17ENST00000310823.8 linkc.2083-60A>G intron_variant Intron 17 of 18 1 NM_003183.6 ENSP00000309968.3

Frequencies

GnomAD3 genomes
AF:
0.416
AC:
63196
AN:
151956
Hom.:
14291
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.306
Gnomad AMI
AF:
0.685
Gnomad AMR
AF:
0.355
Gnomad ASJ
AF:
0.545
Gnomad EAS
AF:
0.0302
Gnomad SAS
AF:
0.344
Gnomad FIN
AF:
0.439
Gnomad MID
AF:
0.620
Gnomad NFE
AF:
0.514
Gnomad OTH
AF:
0.470
GnomAD4 exome
AF:
0.474
AC:
629083
AN:
1327134
Hom.:
156949
AF XY:
0.474
AC XY:
315846
AN XY:
666262
show subpopulations
African (AFR)
AF:
0.311
AC:
9516
AN:
30618
American (AMR)
AF:
0.259
AC:
11179
AN:
43160
Ashkenazi Jewish (ASJ)
AF:
0.546
AC:
13387
AN:
24538
East Asian (EAS)
AF:
0.0231
AC:
900
AN:
38966
South Asian (SAS)
AF:
0.366
AC:
29717
AN:
81244
European-Finnish (FIN)
AF:
0.456
AC:
23762
AN:
52094
Middle Eastern (MID)
AF:
0.606
AC:
3317
AN:
5478
European-Non Finnish (NFE)
AF:
0.514
AC:
510924
AN:
994982
Other (OTH)
AF:
0.471
AC:
26381
AN:
56054
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
14859
29717
44576
59434
74293
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13728
27456
41184
54912
68640
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.416
AC:
63225
AN:
152074
Hom.:
14292
Cov.:
32
AF XY:
0.408
AC XY:
30296
AN XY:
74334
show subpopulations
African (AFR)
AF:
0.307
AC:
12729
AN:
41504
American (AMR)
AF:
0.354
AC:
5407
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.545
AC:
1892
AN:
3472
East Asian (EAS)
AF:
0.0301
AC:
156
AN:
5188
South Asian (SAS)
AF:
0.343
AC:
1654
AN:
4818
European-Finnish (FIN)
AF:
0.439
AC:
4634
AN:
10544
Middle Eastern (MID)
AF:
0.619
AC:
182
AN:
294
European-Non Finnish (NFE)
AF:
0.514
AC:
34963
AN:
67958
Other (OTH)
AF:
0.467
AC:
986
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1806
3611
5417
7222
9028
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
574
1148
1722
2296
2870
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.488
Hom.:
52708
Bravo
AF:
0.403
Asia WGS
AF:
0.206
AC:
717
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Nov 10, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Nov 12, 2023
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 54% of patients studied by a panel of primary immunodeficiencies. Number of patients: 52. Only high quality variants are reported. -

Inflammatory skin and bowel disease, neonatal, 1 Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.91
CADD
Benign
0.17
DANN
Benign
0.70
PhyloP100
-2.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs10495562; hg19: chr2-9631340; API